December 11, 2018 PR-M12-18-NI-032
DUBLIN--(BUSINESS WIRE)--The "Global Anti-obesity Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The anti-obesity drugs market is projected to register a CAGR of almost 8% by 2023.
The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic of obesity and type 2 diabetes is increasing. This demands increasing focus on the drugs that can control obesity and diabetes.
Global increase in both incidence and prevalence of obesity
The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.
Limited reimbursement for anti-obesity drugs
Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. Bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.
Market Trends
Key Players
Topics Covered
1. Executive Summary
2. Scope of the Report
3. Research Methodology
4. Market Landscape
5. Market Sizing
6. Five Forces Analysis
7. Pipeline Analysis
8. Market Segmentation by Drugs Based on Class of Obesity
9. Market Segmentation by Mechanism of Action
10. Customer Landscape
11. Regional Landscape
12. Decision Framework
13. Drivers and Challenges
14. Market Trends
15. Vendor Landscape
16. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/k3n82x/worldwide?w=4
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Anti-Obesity Drugs
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
Our purpose is simple - to enable intelligent decision making.
15 years ago we began selling market research reports. Today we are the world's largest market research store - connecting global information professionals with market insights and analysis from 1,700 research teams based across 81 countries.
We are proud to count over 450 of the Fortune 500 as our clients.